Sales 2024 * | 17.57M 1.38B | Sales 2025 * | 29.87M 2.34B | Capitalization | 58.24M 4.57B |
---|---|---|---|---|---|
Net income 2024 * | -35M -2.75B | Net income 2025 * | -16M -1.26B | EV / Sales 2024 * | 3.31 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.95 x |
P/E ratio 2024 * |
-2.43
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
Latest transcript on BioLineRX Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 23/05/09 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 31/12/08 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 23/02/14 |
Avraham Molcho
BRD | Director/Board Member | 66 | 31/12/09 |
Aharon Schwartz
CHM | Chairman | 80 | 31/12/03 |
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |